Type 2 diabetes (T2D) is a chronic, progressive metabolic disease in which the body becomes resistant to insulin, most often as a result of obesity and a sedentary lifestyle. The primary goal of…
How Are Payer Strategies and Prescriber Preferences Shaping the Non-Insulin Treatment Algorithm? Although a high opportunity market, the therapeutic space for type 2 diabetes (T2D) is set to…
A Focus on Prescribing Trends and Payer Strategy for Diabetic Macular Edema and Diabetic Nephropathy Patients with type 2 diabetes (T2D) often present with multiple comorbidities, which boosts…
Graft versus host disease (GVHD) is a potentially life-threatening complication of an allogeneic hematopoietic stem cell transplant (HCST). Improvements in allogeneic HSCT strategies have expanded…
The type 2 diabetes (T2D) therapy market in Latin America (LatAm) presents a large commercial opportunity to drug manufacturers. The prevalence of T2D in LatAm is high and is expected to increase,…
The launches of sipuleucel-T (Dendreon’s Provenge) and ipilimumab (Bristol-Myers Squibb’s Yervoy) in 2010 and 2011, respectively, represented the first notable immunotherapy approvals in…
Although the postoperative pain market is sizeable in terms of both dollars and the potential patient pool, treatment is very fragmented, with many drugs and formulations available within each drug…
LaunchTrends®: Perjeta and Kadcyla is a series of four post-launch syndicated reports designed to track physician perception and uptake of newly launched Perjeta (Roche/Genentech’s pertuzumab)…